JG
SGMO

Jefferies Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Jefferies Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50,920
Closed -$461K – 2940
2019
Q3 		$461K Buy
+50,920
New +$571K ﹤0.01% 1929
2018
Q1 		– Sell
-18,005
Closed -$295K – 2651
2017
Q4 		$295K Buy
+18,005
New +$268K ﹤0.01% 2024
2015
Q3 		– Sell
-3,887
Closed -$43K – 2937
2015
Q2 		$43K Buy
+3,887
New +$50.1K ﹤0.01% 2480
2015
Q1 		– Sell
-63,167
Closed -$961K – 2350
2014
Q4 		$961K Buy
63,167
+27,552
+77% +$335K 0.01% 993
2014
Q3 		$384K Buy
+35,615
New +$465K ﹤0.01% 1457
2013
Q4 		– Sell
-11,224
Closed -$118K – 2188
2013
Q3 		$118K Buy
+11,224
New +$111K ﹤0.01% 1694

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's SGMO Position: Q4 2019 in Review

Jefferies Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2019, closing a stake of 50,920 shares — an estimated $461K sold.

Jefferies Group first reported a position in SGMO in Q3 2013 and held it in 6 quarters. The position peaked at $961K in Q4 2014. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2019.

  • Jefferies Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2019 after selling out during the quarter.
  • Jefferies Group sold 50,920 SANGAMO THERAPEUTICS INC shares in Q4 2019, an estimated $461K.
  • Jefferies Group first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 6 quarters.
  • Jefferies Group's SANGAMO THERAPEUTICS INC position peaked at $961K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.